Announcement Date. The definition of “Announcement Date” in Section 12.1(l) of the Equity Definitions is hereby amended by (i) replacing the words “a firm” with the word “any” in the second and fourth lines thereof, (ii) replacing the word “leads to the” with the words “, if completed, would lead to a” in the third and the fifth lines thereof, (iii) replacing the words “voting shares” with the word “Shares” in the fifth line thereof, and (iv) inserting the words “by any entity” after the word “announcement” in the second and the fourth lines thereof. Nationalization, Insolvency or Delisting: Cancellation and Payment (Calculation Agent Determination); provided that, in addition to the provisions of Section 12.6(a)(iii) of the Equity Definitions, it will also constitute a Delisting if the Exchange is located in the United States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors); if the Shares are immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors), such exchange or quotation system shall thereafter be deemed to be the Exchange. Additional Disruption Events: Change in Law: Applicable; provided that (i) Section 12.9(a)(ii) of the Equity Definitions is hereby amended by replacing the parenthetical beginning after the word “regulation” in the second line thereof with the words “(including, for the avoidance of doubt and without limitation, (x) any tax law or (y) adoption or promulgation of new regulations authorized or mandated by existing statute),” and (ii) Section 12.9(a)(ii)(X) of the Equity Definitions is hereby amended by replacing the word “Shares” with the phrase “Hedge Positions.” Failure to Deliver: Not Applicable Insolvency Filing: Applicable Hedging Disruption: Applicable; provided that:
Announcement Date. “Announcement Date” shall mean the date on which the CDFI Fund announces the Recipients of CMF Awards under the applicable NOFA, as indicated on the signature page of this Assistance Agreement.
Announcement Date. This is normally not more than 14 days after the Allocation Date. It is the date on which the WCF MC announces the players who have been awarded Ranking Places and Wild Card Places.
Announcement Date. The definition of “Announcement Date” in Section 12.1 of the Equity Definitions shall be amended by (i) replacing the word “leads to the” in the third and the fifth lines thereof with the words “, if completed, would lead to a”; (ii) replacing the words “voting shares” in the fifth line thereof with the word “Shares”; and (iii) inserting the words “by any entity that is likely to be a party to the transaction” after the word “announcement” in the second and the fourth lines thereof; (iv) replacing the words “a firm” with the word “any” in the second and fourth lines thereof; (v) inserting the words “or to explore the possibility of engaging in” after the words “engage in” in the second line thereto; and (vi) inserting the words “or to explore the possibility of purchasing or otherwise obtaining” after the word “obtain” in the fourth line thereto.
Announcement Date. Section 1.8(a)(ii)........... 4
Announcement Date. The Programme will be announced by a repeated one-round public tender in research, experimental development and innovations (hereinafter referred to as the “Public Tender”). It is expected that between 2010 and 2013 one Public Tender will be announced every year. The first Public Tender will be announced in April 2010.
Announcement Date. If you want to be considered for all the retainer contracts, what do you put here?
Announcement Date. Feb 04 2013 205 : sum of upfront and potential development and commercial Deal value, US$m: milestone payments • Details • Financials • Termsheet • Press Release • Filing Data • Contract Details Announcement date: Feb 04 2013 Start date: Feb 03 2013 Bigbiotech Bigpharma Industry sectors: Biotech Pharmaceutical Compound name: ALN-PCSsc Asset type: Compound Therapy areas: Cardiovascular » Hypercholesterolemia Biological compounds Peptides Technology types: Deal components: Stages of development: Proteomics RNA therapeutics Small molecules Development Licensing Marketing Preclinical Phase I Financials Deal value, US$m: 205 : sum of upfront and potential development and commercial milestone payments Upfront, US$m: 25 : sum of upfront payment Milestones, US$m: 180 : sum of potential development and commercial milestone payments n/d : scaled double-digit royalties on global products sales of ALN-PCS Royalty rates, %: products Termsheet The Medicines Company and Alnylam Pharmaceuticals they have formed an exclusive global alliance for the development and commercialization of Alnylam’s ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that regulates low-density lipoprotein (LDL) receptor levels on hepatocytes; gain-of-function human mutations in PCSK9 are associated with hypercholesterolemia while loss-of-function mutations are associated with lower levels of LDL cholesterol and a reduced risk of cardiovascular disease. ALN-PCS is a PCSK9 synthesis inhibitor that reduces intracellular and extracellular levels of PCSK9 resulting in lowered plasma levels of LDL-C. The Medicines Company and Alnylam intend to collaborate on the advancement of the ALN-PCS program. Alnylam’s ALN-PCS program includes ALN-PCS02 - an intravenously administered RNAi therapeutic which has completed a Phase I trial, and ALN-PCSsc - a subcutaneously administered RNAi therapeutic currently in pre-clinical development. Alnylam will continue the program for an estimated one to two years to complete certain pre-clinical and Phase I clinical studies. The Medicines Company is responsible for leading and funding development from Phase II forward and commercializing the ALN-PCS program if successful. Under the terms of the agreement, The Medicines Company will make an upfront cash payment of $25 million to Alnylam. Alnylam may also receive potential development and commercial milestone payments of up to $180 m...
Announcement Date. Notwithstanding Section 12.1(l) of the Equity Definitions, an “Announcement Date” means, in respect of an Announcement Event, the date on which such Announcement Event occurs. Consequences of Merger Events: Merger Event:
Announcement Date. The definition of “Announcement Date” in Section 12.1 of the Equity Definitions shall be amended by (i) replacing the word “leads to the” in the third and the fifth lines thereof with the words “, if completed, would lead to a”; (ii) replacing the words “voting shares” in the fifth line thereof with the word “Shares”; (iii) inserting the words “by any entity” after the word “announcement” in the second and the fourth lines thereof; (iv) replacing the words “a firm intention” with the words “(a) any intention, or (b) any substantial steps taken,” in the second and fourth lines thereof.
